Effect of LIMAI on Low-Density Lipoprotein Cholesterol Absorption
Cardiovascular diseasesand cerebrovascular diseases are collectively referred to as cardiovascular and cerebrovascular diseases, and refer to ischaemia or hemorrhage in the heart, brain and systemic tissues due to hyperlipidemia, blood viscosity, atherosclerosis, and hypertension. disease. Cardiovascular and cerebrovascular disease is a common disease that seriously threatens humans, especially those aged over 50, and has high prevalence, high disability and high mortality. The high concentration of low-density lipoprotein cholesterol is a risk factor for cardiovascular and cerebrovascular diseases.
Studies have shown that the absorption of cholesterol in the intestine requires the transport of NPC1L1 protein, which seizes free cholesterol and transports it to intestinal epithelial cells and is absorbed by the intestine. Through experiments, the researchers found that LIMA1, NPC1L1, and myosin Vb coexist in the small intestine. Myosin Vb is also a protein involved in the intracellular and intercellular transport of substances, and can remove chemicals from the cell membrane. Inside the cell, these three seem to be a "binding relationship." The LIMA1 protein is a "scaffold protein". The scaffold protein is a "protein-specific glue". He can bind at least two proteins at the same time, and binds these functionally related proteins together to ensure the specific and efficient life activities they participate in. Sex. Therefore, when the LIMA1 protein is inhibited, the absorbed cholesterol is reduced.
This study breaks the balance of cholesterol absorption and lays a solid foundation for the development of new drugs.
Biobool developed the LIMA1-related ELISA kit and was welcomed by researchers.